Sales 2024 * | 624M 52.1B | Sales 2025 * | 715M 59.66B | Capitalization | 2.48B 207B |
---|---|---|---|---|---|
Net income 2024 * | 111M 9.26B | Net income 2025 * | 200M 16.69B | EV / Sales 2024 * | 2.92 x |
Net cash position 2024 * | 659M 54.99B | Net cash position 2025 * | 748M 62.44B | EV / Sales 2025 * | 2.42 x |
P/E ratio 2024 * |
23
x | P/E ratio 2025 * |
15.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 68.25% |
Latest transcript on Corcept Therapeutics
Managers | Title | Age | Since |
---|---|---|---|
Joseph Belanoff
FOU | Founder | 66 | 13/98/13 |
Atabak Mokari
DFI | Director of Finance/CFO | 47 | 01/21/01 |
Joseph Lyon
CTO | Chief Tech/Sci/R&D Officer | 46 | 01/12/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Belanoff
FOU | Founder | 66 | 13/98/13 |
Gregg Alton
BRD | Director/Board Member | 58 | 12/20/12 |
George Baker
BRD | Director/Board Member | 81 | 01/99/01 |
1st Jan change | Capi. | |
---|---|---|
+33.25% | 699B | |
+26.04% | 571B | |
-3.55% | 364B | |
+18.16% | 326B | |
+4.36% | 286B | |
+15.02% | 236B | |
+4.85% | 198B | |
-10.18% | 194B | |
-3.69% | 149B |